Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Realcan Pharmaceutical Group Co (SZSE:002589) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Realcan Pharmaceutical Group Co's EV-to-EBIT for today is
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil.
Realcan Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥213 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Realcan Pharmaceutical Group Co's EV-to-EBITDA for today is:
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil.
Realcan Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥213 Mil.
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil.
Realcan Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7,167 Mil.
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil.
Realcan Pharmaceutical Group Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-5 Mil.
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil.
Realcan Pharmaceutical Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co Enterprise Value Related Terms
Realcan Pharmaceutical Group Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co Enterprise Value Chart
SZSE:002589 vs MCK, COR, CAH: Enterprise Value Comparison
For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Realcan Pharmaceutical Group Co Enterprise Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Realcan Pharmaceutical Group Co's Enterprise Value falls into.
Realcan Pharmaceutical Group Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co (SZSE:002589) has a Enterprise Value of ¥4,158 Mil as of Sep. 13, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Realcan Pharmaceutical Group Co and its competitors.
Is Realcan Pharmaceutical Group Co's Enterprise Value too high?
Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil. Overall, Realcan Pharmaceutical Group Co has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Realcan Pharmaceutical Group Co's Enterprise Value compare to MCK and COR?
Realcan Pharmaceutical Group Co's Enterprise Value of ¥4,158 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Distribution company?
A good Enterprise Value depends on the Medical Distribution industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Realcan Pharmaceutical Group Co and its competitors. Realcan Pharmaceutical Group Co's current Enterprise Value is ¥4,158 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Realcan Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co (SZSE:002589) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥2.44, compared to a current price of ¥3.05 — trading 25% above its estimated fair value. The current Enterprise Value is ¥4,158 Mil. Realcan Pharmaceutical Group Co's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Realcan Pharmaceutical Group Co (SZSE:002589), the current Enterprise Value is ¥4,158 Mil as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Realcan Pharmaceutical Group Co (SZSE:002589) Overvalued in 2026?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥3.05 is trading 25% above its estimated GF Value™ of ¥2.44.
GuruFocus considers Realcan Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SZSE:002589:
Enterprise Value: ¥4,158 Mil
GF Value™: ¥2.44 vs. price of ¥3.05 (25% above fair value)
No single metric tells the full story. See the SZSE:002589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
53GF Score
Get the complete analysis for SZSE:002589
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002589 has been successfully added to your 
